CD274 and esophageal squamous cell carcinoma: As for Atezolizumab, Thar Min AK et al. showed that PD-L1 expression on tumor cells was positively correlated with EMT status in esophageal squamous cell carcinoma (ESCC) and EMT-converted ESCC indicated the upregulation of PD-L1 at both protein (total and surface) and mRNA levels, which provided a strong rationale for the clinical use of Atezolizumab for ESCC patients (45).